18 January 2024
18 January 2024
The Phase IIa results of IPL344 gives the company confidence to progress to a pivotal trial of the candidate in ALS.
The company’s lead antibiotic candidate ibezapolstat showed a 94% eradication rate of fecal C. difficile at day three of treatment.
The proceeds will fund a clinical trial of Comanche’s siRNA therapy in pregnant preeclamptic women that will start later in the year.
The US regulator approved the investigational new drug (IND) application for a trial of the narmafotinib plus FOLFIRINOX chemotherapy regimen.
The first subject for the trial was enrolled at Tartu University Hospital in Estonia.
The Phase IIb trial will enrol 146 participants to assess the investigational therapy IGC-AD1 versus a placebo.
The results from this clinical trial will be presented at the ASCO Gastrointestinal Cancers Symposium on 19 January.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
